Literature DB >> 3422751

Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection.

B C Guild1, R C Mulligan, P Gros, D E Housman.   

Abstract

We have constructed a retrovirus expression vector that carries the murine mdr cDNA transcribed under the control of the human H4 histone promoter to examine the feasibility of efficiently transferring a multidrug resistance phenotype to cells without requiring drug selection. This approach will facilitate the transfer of mdr cDNA to hematopoietic progenitor cells for the study of multidrug resistance in vivo. The retrovirus vector pHmdr has been used for transmission and expression of the mdr cDNA in initially drug-sensitive NIH 3T3 fibroblasts. Selection of pHmdr infectants in the cytotoxic agents colchicine or doxorubicin gave rise to highly multidrug-resistant colonies containing a single gene copy of the vector. Moreover, in the analysis of 12 cloned unselected NIH 3T3 cell infectants, a multidrug resistance phenotype was conferred by as few as two copies of the pHmdr vector. Overexpression of the mdr cDNA in drug-selected and unselected pHmdr infectants was directly related to cell survival in three cytotoxic agents tested. These results hold significant implications for the study of multidrug resistance in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422751      PMCID: PMC279820          DOI: 10.1073/pnas.85.5.1595

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype.

Authors:  J M Croop; B C Guild; P Gros; D E Housman
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

2.  Isolation and characterization of an anthracycline-resistant human leukemic cell line.

Authors:  K Bhalla; A Hindenburg; R N Taub; S Grant
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

3.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.

Authors:  J L Biedler; H Riehm
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

4.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

5.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

6.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

Authors:  J R Riordan; K Deuchars; N Kartner; N Alon; J Trent; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

7.  Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

Authors:  A Fojo; S Akiyama; M M Gottesman; I Pastan
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

8.  Isolation and genetic characterization of human KB cell lines resistant to multiple drugs.

Authors:  S Akiyama; A Fojo; J A Hanover; I Pastan; M M Gottesman
Journal:  Somat Cell Mol Genet       Date:  1985-03

9.  High-level, unstable adriamycin resistance in a Chinese hamster mutant cell line with double minute chromosomes.

Authors:  N Howell; T A Belli; L T Zaczkiewicz; J A Belli
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  18 in total

1.  Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1.

Authors:  P C Brown; J A Silverman
Journal:  Nucleic Acids Res       Date:  1996-08-15       Impact factor: 16.971

2.  Recombinant retroviruses encoding cell surface antigens as selectable markers.

Authors:  R K Strair; M J Towle; B R Smith
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

3.  Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia.

Authors:  H Galski; M Sullivan; M C Willingham; K V Chin; M M Gottesman; I Pastan; G T Merlino
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

4.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.

Authors:  J M Croop; M Raymond; D Haber; A Devault; R J Arceci; P Gros; D E Housman
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

5.  Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo.

Authors:  B C Guild; M H Finer; D E Housman; R C Mulligan
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

Review 6.  Effects of phosphorylation of P-glycoprotein on multidrug resistance.

Authors:  U A Germann; T C Chambers; S V Ambudkar; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

7.  Development of improved adenosine deaminase retroviral vectors.

Authors:  M Onodera; D M Nelson; A Yachie; G J Jagadeesh; B A Bunnell; R A Morgan; R M Blaese
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 8.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Cloning and regulation of the rat mdr2 gene.

Authors:  P C Brown; S S Thorgeirsson; J A Silverman
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

Review 10.  Molecular cytogenetics of multiple drug resistance.

Authors:  P V Schoenlein
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.